New allergy drug Exl-111 enters first human tests
Symptom relief
Recruiting now
This early-stage trial tests the safety of a new drug called Exl-111 for allergic diseases. It involves 70 healthy adults aged 18-55. Participants receive either the drug, a placebo, or an active comparator (omalizumab) to see how the body handles it and if any side effects occur…
Phase: PHASE1 • Sponsor: Excellergy Inc. • Aim: Symptom relief
Last updated May 07, 2026 18:38 UTC